Join Apellis Pharmaceuticals for Insightful Q3 2025 Call

Author: Owen Jenkins Updated: 10-16-2025 07:07 AM

Join the Upcoming Conference Call by Apellis Pharmaceuticals

On October 30, 2025, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will host an important conference call at 8:30 a.m. ET to delve into their financial performance for the third quarter of 2025. This event presents investors and stakeholders with a valuable opportunity to hear directly from the company's leadership about their recent accomplishments and future outlook.

How to Participate in the Conference Call

Participants interested in joining the live call via phone are encouraged to pre-register for the event. This ensures a smooth experience with the ability to engage and ask questions. Additionally, a live audio webcast, including slides from the presentation, will be available on Apellis Pharmaceuticals’ official website under the “Events and Presentations” section in the “Investors and Media” area. If you miss the live event, a playback option will be available for 90 days following the presentation.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals stands at the forefront of biopharmaceutical innovation, specializing in complement science aimed at developing transformative therapies for serious diseases. The company is renowned for introducing a new class of complement medicine, marking a significant advancement in medical treatment with two approved C3-targeting therapies that address four critical diseases. A notable highlight includes the launch of the first-ever therapy for geographic atrophy, a leading cause of blindness, along with groundbreaking treatments for rare kidney diseases affecting patients aged 12 and older.

Focus on Innovation and Patient Care

Apellis is continuously striving to unlock additional potential therapies targeting C3, demonstrating a commitment to addressing unmet medical needs. This dedication reflects their vision of enhancing patient outcomes through innovative solutions.

Stay Connected with Apellis

To learn more about Apellis Pharmaceuticals and their ongoing research and developments, you can visit their website. Follow their journey on LinkedIn and other social media platforms to stay updated on their latest news and breakthroughs.

Investor Relations Contact

For any inquiries or further information, please reach out to Eva Stroynowski at Apellis Pharmaceuticals. You can contact her via email or by phone at 617.938.6229.

Frequently Asked Questions

What is the purpose of the conference call on October 30, 2025?

The conference call is intended to discuss the third quarter financial results of Apellis Pharmaceuticals and provide insights into their strategic direction.

How can I access the conference call?

You can access the conference call by pre-registering for the phone line or by visiting the company's website for the audio webcast.

Who should attend the call?

Investors, analysts, and stakeholders interested in the financial performance and strategy of Apellis Pharmaceuticals are encouraged to attend.

What recent breakthroughs has Apellis achieved?

Apellis has made significant strides in complement medicine, including therapies for geographic atrophy and rare kidney diseases.

How can I stay informed about Apellis Pharmaceuticals?

You can stay updated by visiting their official website and following them on social media channels like LinkedIn.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.